Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy
Sabino Strippoli(Istituto Tumori Bari), Michele Guida(Istituto Tumori Bari), Annarita Fanizzi(Istituto Tumori Bari), Francesco Macina(Istituto Tumori Bari), F. Mele(Istituto Tumori Bari), Michele Traversa(University of Brescia), Annalisa Nardone(Istituto Tumori Bari), Ivana De Risi(Istituto Tumori Bari), Livia Fucci(Istituto Tumori Bari), Elisabetta Montagna(Policlinico San Matteo Fondazione), Raffaella Massafra(Istituto Tumori Bari), Anna Albano(Istituto Tumori Bari), Angela Monica Sciacovelli(Istituto Tumori Bari), Andrea Armenio(Istituto Tumori Bari), Raffaele Filotico(University of Bari Aldo Moro), Davide Quaresmini(Istituto Tumori Bari), Federica De Luca(Istituto Tumori Bari), Eustachio Ruggieri(Istituto Tumori Bari), Francesco Figliuolo(Istituto Tumori Bari), Stefania Tommasi(Istituto Tumori Bari), Simona Ferraiuolo(Istituto Tumori Bari)
Cited by 46
Related Papers
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
|Journal of Clinical Oncology|2022|231
Accuracy in melanoma detection: A 10-year multicenter survey
|Journal of the American Academy of Dermatology|2011|209
The E6 and E7 Proteins of the Cutaneous Human Papillomavirus Type 38 Display Transforming Properties
|Journal of Virology|2003|187
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
|Journal of Translational Medicine|2014|164